MY168662A - Attenuated bacteria for use in a vaccine - Google Patents

Attenuated bacteria for use in a vaccine

Info

Publication number
MY168662A
MY168662A MYPI2012005700A MYPI2012005700A MY168662A MY 168662 A MY168662 A MY 168662A MY PI2012005700 A MYPI2012005700 A MY PI2012005700A MY PI2012005700 A MYPI2012005700 A MY PI2012005700A MY 168662 A MY168662 A MY 168662A
Authority
MY
Malaysia
Prior art keywords
sequences
polypeptide
relates
pasteurella
bacteria
Prior art date
Application number
MYPI2012005700A
Inventor
Abdul Rahim Raha
Zamri Bin Saad Mohd
Zakaria Zunita
Sarah Othman Siti
Original Assignee
Univ Putra Malaysia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Putra Malaysia filed Critical Univ Putra Malaysia
Priority to MYPI2012005700A priority Critical patent/MY168662A/en
Publication of MY168662A publication Critical patent/MY168662A/en

Links

Landscapes

  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to an attenuated bacterium for use as a medicament which stimulates protective immunity against normal growth of pathogenic Pasteurella bacteria. the invention also relates to immunogenic preparations including vaccines against disease caused by infection by a virulent Pasteurella strain and tools for the generation of immunological and diagnostic reagents. Further, the present invention relates to live attenuated recombinant bacteria carrying a gene and vaccines based thereon that can be administered to animals, particularly ruminants to provide protective immunity against challenge by Pasteurella bacteria. Also disclosed are the bacterium polypeptide and includes polypeptide sequences, gene sequences encoding the polypeptide, vectors to contain the said sequences, and host cells transformed with the said vectors which include nucleotide sequences of the polypeptide sequences. Figure 2
MYPI2012005700A 2007-02-13 2007-02-13 Attenuated bacteria for use in a vaccine MY168662A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MYPI2012005700A MY168662A (en) 2007-02-13 2007-02-13 Attenuated bacteria for use in a vaccine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MYPI2012005700A MY168662A (en) 2007-02-13 2007-02-13 Attenuated bacteria for use in a vaccine

Publications (1)

Publication Number Publication Date
MY168662A true MY168662A (en) 2018-11-29

Family

ID=79170405

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2012005700A MY168662A (en) 2007-02-13 2007-02-13 Attenuated bacteria for use in a vaccine

Country Status (1)

Country Link
MY (1) MY168662A (en)

Similar Documents

Publication Publication Date Title
Simionatto et al. Mycoplasma hyopneumoniae: from disease to vaccine development
Dhama et al. DNA vaccines and their applications in veterinary practice: current perspectives
Goel et al. Intradermal immunization with outer membrane protein 25 protects Balb/c mice from virulent B. abortus 544
US11103569B2 (en) Vaccine for protection against Streptococcus suis
DK2566507T3 (en) Bioconjugate vaccines with capsular gram-positive bacteria
WO2008039408A3 (en) Live bacterial vaccines for viral infection prophylaxis or treatment
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
RU2014134365A (en) CLOSTRIDIUM DIFFICILE VACCINES INCLUDING RECOMBINANT TOXINS
MX2009006178A (en) Salmonella vaccine.
NZ597858A (en) Vaccines and compositions against streptococcus pneumoniae
MXPA03011815A (en) Mycoplasma bovis vaccine and methods of reducing pneumonia in animals.
Estein et al. The polymeric antigen BLSOmp31 confers protection against Brucella ovis infection in rams
BRPI0816134A2 (en) Herpesvirus, DNA sequence, vector, cell, virus, method for producing infectious particles, infectious particles, vaccine, use of herpesvirus or DNA sequence or vector or infectious particles, and method for preventive and / or treatment. treatment of a disease.
JP2012521391A (en) Vaccines to protect against various serotypes of Streptococcus bacterium
CA2926190C (en) Haemophilus parasuis vaccine serovar type four
NZ598605A (en) Vaccine against african horse sickness virus
CN101603024B (en) Porcine mycoplasmal pneumonia and porcine infectious actinobacillus pleuropneumoniae serum 1 type gene engineering strain vaccine and application thereof
EP3876980A1 (en) A vaccine for protection against streptococcus suis
CN101880647A (en) Recombinant salmonella choleraesuis, bivalent genetic engineering vaccine and application
CN102732473B (en) The recombinant salmonella choleraesuis of expression mycoplasma hyopneumoniae p46 albumen and preparation method and application
EP2655403A1 (en) Vaccines with live bacterial isolates for systemic administration
MY168662A (en) Attenuated bacteria for use in a vaccine
MY188912A (en) Attenuated bacteria for use in a vaccine
MY177159A (en) Attenuated bacteria for use in a vaccine
MY177164A (en) Attenuated bacteria for use in a vaccine